Stay updated on GX-188E + Pembrolizumab in HPV+ Cervical Cancer Clinical Trial
Sign up to get notified when there's something new on the GX-188E + Pembrolizumab in HPV+ Cervical Cancer Clinical Trial page.

Latest updates to the GX-188E + Pembrolizumab in HPV+ Cervical Cancer Clinical Trial page
- Check4 days agoChange DetectedUpdated the page revision from v3.0.1 to v3.0.2. The old revision label was removed and the Back to Top element was dropped; no other core content changes were detected.SummaryDifference0.3%
- Check11 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.SummaryDifference0.3%
- Check18 days agoChange DetectedThe web page has been updated to include specific facility names and locations in South Korea, along with a new reference to a clinical trial involving the GX-188 vaccine and pembrolizumab. The revision number has also been updated.SummaryDifference7%
- Check26 days agoNo Change Detected
- Check33 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%
- Check40 days agoChange DetectedThe web page has been updated from version 2.16.10 to version 2.16.11.SummaryDifference0.1%
- Check47 days agoChange DetectedThe webpage has been updated with new results and evaluation dates for a clinical study involving tirvalimogene teraplasmid, including specific metrics for efficacy and safety. Additionally, previous results and maintenance alerts have been removed.SummaryDifference7%
Stay in the know with updates to GX-188E + Pembrolizumab in HPV+ Cervical Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the GX-188E + Pembrolizumab in HPV+ Cervical Cancer Clinical Trial page.